hepatocellular carcinoma (HCC)
Conditions
Interventions
Low lymphatic vessel density group:None
High lymphatic vessel density group:None
Sponsors
The Second Affiliated Hospital of Kunming Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Patients with age of 18-65 years, including male and female 2.Treatment-naive patients, with BCLC stage 0 or A, received radical hepatectomy in The Second Affiliated Hospital of Kunming Medical University from December 1, 2023 to November 30, 2024. Postoperative pathology confirm: HCC with R0 resection, peripheral liver cirrhosis, MVI M0, and no risk factors for recurrence such as satellite nodular metastasis 3.ECOG score returned to 0-1 within 14 days after surgery 4.Child-Pugh score returned to Grade A within 14 days after surgery 5.Written informed consent
Exclusion criteria
Exclusion criteria: 1.Preoperative lymphocyte absolute value was less than 1.1×10^9/L 2.Patients with severe or life-threatening liver, kidney, cardiovascular and cerebrovascular diseases 3.Pregnant or have a family plan within one year of the start of treatment 4.Allergic to envafolimab 5.Other conditions were not suitable for inclusion judged by researchers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence-free survival;Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment-related adverse effects rate;Grade 3-4 adverse effects rate; | — |
Countries
China
Contacts
Public ContactKe Yang
The Second Affiliated Hospital of Kunming Medical University
Outcome results
None listed